valproic acid has been researched along with 17-alpha-hydroxyprogesterone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Cockrell, JE; Legro, RS; McAllister, JM; Nelson-DeGrave, VL; Strauss, JF; Wickenheisser, JK; Wood, JR | 1 |
| Bahtiyar, G; Sacerdote, AS; Weiss, K | 1 |
1 review(s) available for valproic acid and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
2 other study(ies) available for valproic acid and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Valproate potentiates androgen biosynthesis in human ovarian theca cells.
Topics: 17-alpha-Hydroxyprogesterone; Acetylation; Adult; Androgens; Androstenedione; Cholesterol Side-Chain Cleavage Enzyme; Dehydroepiandrosterone; Female; Gene Expression; Histones; Humans; Phosphoproteins; Polycystic Ovary Syndrome; Progesterone; Steroid 17-alpha-Hydroxylase; Theca Cells; Valproic Acid | 2004 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid | 2007 |